



BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS", NO.299, THAMBU CHETTY STREET, CHENNAI – 600001, TAMIL NADU, INDIA
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com
CIN: L24294TN1995PLCO30698

Date: August 13, 2024

To

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001.	National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai – 400051.
Scrip Code: 532989	Scrip Code: BAFNAPH

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 Of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Sale / Disposal of Manufacturing Undertaking

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we hereby inform you that the Board of Directors of the Company, at its meeting held on August 13, 2024, has approved the sale/disposal of the Company's manufacturing unit located at No. 13, S.V. Koil Street, Madhavaram, Chennai – 600060, to M/s Navron Pharma Private Limited ("the Buyer"), which is subject to the fulfillment of conditions prescribed by the Board of Directors and the execution of the necessary agreement(s).

This disclosure is made pursuant to Regulation 30, read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The information required under SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, will be submitted once the agreement is executed between the Company and the Buyer and the proposed transaction is consummated.

We request you to take the information and documents on record.

Thanking You.

For **BAFNA PHARMACEUTICALS LIMITED**

Mohanachandran A
Company Secretary